ICON Public Limited Company
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ICON Public Limited Company (NasdaqGS: ICLR), a leading global clinical research organization (CRO), provides outsourced drug development, commercialization and healthcare intelligence services to pharmaceutical, biotechnology, medical device and government organizations. The company offers a comprehensive portfolio of services including clinical trial management from Phase I through IV; early phase clinical and bioanalytical solutions; cardiac safety solutions encompassing ECG, Holter monitoring, ECHO and MUGA studies; site and patient recruitment with real-world data integration; specialty laboratory services for precision medicine, biomarkers and vaccine testing; market access, pricing and reimbursement consulting; real-world evidence generation; medical imaging; language services; consulting and strategic solutions; decentralized and hybrid trials; and commercial positioning with health economics and outcomes research. ICON operates over 95 locations across approximately 45 countries in the Americas, Europe, Asia-Pacific and Africa, targeting biopharma sponsors and supporting therapeutic areas such as oncology, rare diseases, infectious diseases and cardiovascular. Founded in 1990 and headquartered in Dublin, Ireland, the company employs around 41,000 professionals worldwide. Recent developments include the acquisition of KCR in 2024, enhancing full-service and functional clinical trial capabilities in Europe; the purchase of HumanFirst in 2024, adding cloud-based technology for patient-centered precision measurement; strong gross business wins of $2.97 billion in Q2 2025, up 10.6% sequentially; a share repurchase program expansion to $1 billion authorized; and updated full-year 2025 revenue guidance of $7.85-$8.15 billion with adjusted EPS of $13.00-$14.00.
Oakmark Concentrated Strategy Q2 2026 Performance Review
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
ICON Announces Pricing of USD 2.15 Billion Notes
ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen
ICON Announces Private Offering of Notes
Icon Plc $ICLR Shares Sold by Avidity Partners Management LP
ICON Announces Results of Annual General Meeting
ICON Public Limited Company (ICLR) Q2 2026 Earnings Call Transcript
Icon Q2 Earnings Call Highlights
Icon PLC (ICLR) Lags Q2 Earnings Estimates
ICON Reports Second Quarter 2026 Results
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials
Icon PLC (ICLR) Up 5.8% Since Last Earnings Report: Can It Continue?
ICON Schedules Second Quarter 2026 Earnings Conference Call
Icon (ICLR) to Release Earnings on Wednesday
AVTR vs. ICLR: Which Stock Should Value Investors Buy Now?
Earnings Preview: Icon PLC (ICLR) Q2 Earnings Expected to Decline
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm
RESERVOIR ANNOUNCES PUBLISHING DEAL WITH MULTI-PLATINUM AND GRAMMY-WINNING HIP-HOP ICON T.I.
ICON Stock and the CRO Trends Shaping Its Next Growth Phase